Welcome to our dedicated page for GSK PLC SEC filings (Ticker: GLAXF), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
GSK PLC (GLAXF) filings document foreign-issuer disclosures for a global biopharma company registered in England and Wales. The record centers on Form 6-K current reports furnished under the Exchange Act, including announcements on product collaborations, capital-return programs, annual general meeting voting results, remuneration matters, board elections, and transaction notifications involving American Depositary Shares.
The filings also describe GSK's securities framework, including ordinary shares and ADS instruments, share repurchases and treasury-share treatment, PDMR transaction reporting, and governance resolutions connected with annual reporting and shareholder approvals. Product-related reports identify bepirovirsen in chronic hepatitis B and outline regulatory, quality, pharmacovigilance, commercial access, and global medical-strategy responsibilities associated with collaboration arrangements.
GSK plc reports the vesting of a 2023 Performance Share Plan award granted to its Chief Financial Officer, Julie Brown. Following performance assessment, 82% of this award vested and 18% lapsed.
The vesting delivered 243,880 Ordinary Shares at a price of £0.00 per share, including dividend equivalents, on 27 April 2026. These vested shares are subject to an additional two-year holding period. The closing price of GSK Ordinary Shares on the vesting date was £20.16.
GSK plc reports the vesting of a 2023 Performance Share Plan award granted to its Chief Financial Officer, Julie Brown. Following performance assessment, 82% of this award vested and 18% lapsed.
The vesting delivered 243,880 Ordinary Shares at a price of £0.00 per share, including dividend equivalents, on 27 April 2026. These vested shares are subject to an additional two-year holding period. The closing price of GSK Ordinary Shares on the vesting date was £20.16.
GSK reports that the US FDA has accepted for priority review a New Drug Application for bepirovirsen, an investigational antisense oligonucleotide for adults with chronic hepatitis B. The FDA has also granted Breakthrough Therapy Designation, adding to the Fast Track Designation awarded in February 2024.
The submission is backed by phase III B-Well 1 and B-Well 2 trials, where bepirovirsen plus standard of care achieved statistically significant, clinically meaningful functional cure rates versus standard of care alone, with an acceptable safety profile. Chronic hepatitis B affects more than 250 million people worldwide, and current standard therapies usually require lifelong treatment with low functional cure rates around 1%. The FDA has assigned 26 October 2026 as the PDUFA goal date.
GSK reports that the US FDA has accepted for priority review a New Drug Application for bepirovirsen, an investigational antisense oligonucleotide for adults with chronic hepatitis B. The FDA has also granted Breakthrough Therapy Designation, adding to the Fast Track Designation awarded in February 2024.
The submission is backed by phase III B-Well 1 and B-Well 2 trials, where bepirovirsen plus standard of care achieved statistically significant, clinically meaningful functional cure rates versus standard of care alone, with an acceptable safety profile. Chronic hepatitis B affects more than 250 million people worldwide, and current standard therapies usually require lifelong treatment with low functional cure rates around 1%. The FDA has assigned 26 October 2026 as the PDUFA goal date.
GSK plc reports that its investigational liver therapy efimosfermin, a once-monthly FGF21-based injection, has received US FDA Breakthrough Therapy designation and EMA PRIME status for treating metabolic dysfunction-associated steatohepatitis (MASH). These regulatory designations are intended to speed development of medicines with strong early evidence in serious diseases.
Phase II data in MASH patients with moderate to advanced (F2/F3) and cirrhotic (F4) fibrosis showed fibrosis improvement and MASH resolution versus placebo, with a generally well‑tolerated safety profile and mostly mild, transient gastrointestinal side effects. Efimosfermin is now in phase III ZENITH-1 and ZENITH-2 trials in F2/F3 patients, with additional phase III studies in F4 MASH planned this year.
MASH is described as a chronic, progressive liver disease affecting up to 5% of the global population and a leading cause of liver transplant in the US and Europe, with limited liver‑specific treatments and no approved options for cirrhotic MASH. GSK highlights efimosfermin’s potential to directly target liver fibrosis and positions it as part of a broader hepatology pipeline in MASH, chronic hepatitis B and alcohol‑associated liver disease.
GSK plc reports that its investigational liver therapy efimosfermin, a once-monthly FGF21-based injection, has received US FDA Breakthrough Therapy designation and EMA PRIME status for treating metabolic dysfunction-associated steatohepatitis (MASH). These regulatory designations are intended to speed development of medicines with strong early evidence in serious diseases.
Phase II data in MASH patients with moderate to advanced (F2/F3) and cirrhotic (F4) fibrosis showed fibrosis improvement and MASH resolution versus placebo, with a generally well‑tolerated safety profile and mostly mild, transient gastrointestinal side effects. Efimosfermin is now in phase III ZENITH-1 and ZENITH-2 trials in F2/F3 patients, with additional phase III studies in F4 MASH planned this year.
MASH is described as a chronic, progressive liver disease affecting up to 5% of the global population and a leading cause of liver transplant in the US and Europe, with limited liver‑specific treatments and no approved options for cirrhotic MASH. GSK highlights efimosfermin’s potential to directly target liver fibrosis and positions it as part of a broader hepatology pipeline in MASH, chronic hepatitis B and alcohol‑associated liver disease.
GSK plc, through its subsidiary TESARO, reports a procedural update in ongoing litigation with AnaptysBio over rights to the cancer drug dostarlimab (Jemperli). The Delaware Chancery Court granted a motion by AnaptysBio to dismiss TESARO's claim for anticipatory breach. GSK notes that the ruling does not address the core contractual dispute and does not affect TESARO's remaining claim for declaratory judgment, which it plans to pursue at trial. Jemperli, the brand name for dostarlimab, is approved in over 35 countries for certain endometrial cancers, and GSK reports significant growth driven by label expansions and an ongoing clinical program in additional cancer types.
GSK plc, through its subsidiary TESARO, reports a procedural update in ongoing litigation with AnaptysBio over rights to the cancer drug dostarlimab (Jemperli). The Delaware Chancery Court granted a motion by AnaptysBio to dismiss TESARO's claim for anticipatory breach. GSK notes that the ruling does not address the core contractual dispute and does not affect TESARO's remaining claim for declaratory judgment, which it plans to pursue at trial. Jemperli, the brand name for dostarlimab, is approved in over 35 countries for certain endometrial cancers, and GSK reports significant growth driven by label expansions and an ongoing clinical program in additional cancer types.
GSK plc reported a routine executive share transaction involving President Maya Martinez-Davis. She acquired notional American Depositary Shares (ADS) within her GSK Executive Supplemental Savings Plan account. The transaction covered 8.572 ADS at a price of $55.7000 per ADS on 2026-04-22 on the New York Stock Exchange.
GSK plc reported a routine executive share transaction involving President Maya Martinez-Davis. She acquired notional American Depositary Shares (ADS) within her GSK Executive Supplemental Savings Plan account. The transaction covered 8.572 ADS at a price of $55.7000 per ADS on 2026-04-22 on the New York Stock Exchange.
GSK plc reports that, on 22 April 2026, it repurchased 965,671 ordinary shares of 31¼ pence each under its existing buyback programme, acting through BNP Paribas. The shares were bought at a volume-weighted average price of 2,081.15p, with prices ranging from 2,073.00p to 2,093.00p.
The repurchased shares will be held as Treasury shares. Since 17 February 2026, GSK has bought 21,487,192 ordinary shares. After this transaction, it holds 261,378,286 shares in treasury and has 4,054,820,748 ordinary shares in issue, giving a total of 4,054,820,748 voting rights. Treasury shares represent 6.45% of voting rights, as confirmed under DTR 5.5.1R.
GSK plc reports that, on 22 April 2026, it repurchased 965,671 ordinary shares of 31¼ pence each under its existing buyback programme, acting through BNP Paribas. The shares were bought at a volume-weighted average price of 2,081.15p, with prices ranging from 2,073.00p to 2,093.00p.
The repurchased shares will be held as Treasury shares. Since 17 February 2026, GSK has bought 21,487,192 ordinary shares. After this transaction, it holds 261,378,286 shares in treasury and has 4,054,820,748 ordinary shares in issue, giving a total of 4,054,820,748 voting rights. Treasury shares represent 6.45% of voting rights, as confirmed under DTR 5.5.1R.
GSK plc reports repurchasing 335,000 ordinary shares on 21 April 2026 as part of its existing buyback programme, using BNP Paribas as broker. The shares, with a nominal value of 31¼ pence each, were bought at prices between 2,074.00p and 2,130.00p, at a volume‑weighted average price of 2,103.08p.
The repurchased shares will be held as treasury shares. After this transaction, GSK holds 260,412,615 shares in treasury and has 4,055,786,419 ordinary shares in issue excluding treasury shares, which equals the total number of voting rights. Treasury shares represent 6.42% of voting rights under DTR 5.5.1R.
GSK plc reports repurchasing 335,000 ordinary shares on 21 April 2026 as part of its existing buyback programme, using BNP Paribas as broker. The shares, with a nominal value of 31¼ pence each, were bought at prices between 2,074.00p and 2,130.00p, at a volume‑weighted average price of 2,103.08p.
The repurchased shares will be held as treasury shares. After this transaction, GSK holds 260,412,615 shares in treasury and has 4,055,786,419 ordinary shares in issue excluding treasury shares, which equals the total number of voting rights. Treasury shares represent 6.42% of voting rights under DTR 5.5.1R.
GSK plc reports that, acting through BNP Paribas, it repurchased 330,000 ordinary shares on 20 April 2026 as part of its existing share buyback programme. The shares, with a nominal value of 31¼ pence each, were bought at prices between 2,134.00p and 2,156.00p per share, with a volume‑weighted average price of 2,141.19p.
The purchased shares will be held as Treasury shares. Since 17 February 2026, GSK has bought 20,186,521 ordinary shares under this programme. After this transaction, GSK will hold 260,077,615 shares in treasury and have 4,056,121,419 ordinary shares in issue, which is also the total number of voting rights. GSK states that, following this purchase, treasury shares represent 6.41% of voting rights.
GSK plc reports that, acting through BNP Paribas, it repurchased 330,000 ordinary shares on 20 April 2026 as part of its existing share buyback programme. The shares, with a nominal value of 31¼ pence each, were bought at prices between 2,134.00p and 2,156.00p per share, with a volume‑weighted average price of 2,141.19p.
The purchased shares will be held as Treasury shares. Since 17 February 2026, GSK has bought 20,186,521 ordinary shares under this programme. After this transaction, GSK will hold 260,077,615 shares in treasury and have 4,056,121,419 ordinary shares in issue, which is also the total number of voting rights. GSK states that, following this purchase, treasury shares represent 6.41% of voting rights.
GSK plc reports that Chief People Officer Diana Conrad acquired 65.267 American Depositary Shares at $58.3499 per ADS on 13 April 2026. The ADSs were acquired through reinvestment of dividends paid on 9 April 2026 on shares held within a GSK pension plan.
GSK plc reports that Chief People Officer Diana Conrad acquired 65.267 American Depositary Shares at $58.3499 per ADS on 13 April 2026. The ADSs were acquired through reinvestment of dividends paid on 9 April 2026 on shares held within a GSK pension plan.
GSK plc received approval in China for Blenrep (belantamab mafodotin) in combination with bortezomib and dexamethasone to treat adults with relapsed or refractory multiple myeloma after at least one prior therapy.
The decision by China’s National Medical Products Administration followed priority review and Breakthrough Therapy Designation for the regimen. It is the only anti-BCMA option approved in second line and beyond multiple myeloma in China, and the only fully outpatient anti-BCMA therapy, allowing 30-minute infusions without hospitalisation.
The DREAMM-7 phase III trial showed the Blenrep combination nearly tripled median progression-free survival to 36.6 months versus 13.4 months for a daratumumab-based triplet, and reduced the risk of death by 42%. Three-year overall survival was 74% for the Blenrep regimen versus 60% for the comparator, with safety broadly consistent with known profiles and manageable eye-related side effects.
GSK plc received approval in China for Blenrep (belantamab mafodotin) in combination with bortezomib and dexamethasone to treat adults with relapsed or refractory multiple myeloma after at least one prior therapy.
The decision by China’s National Medical Products Administration followed priority review and Breakthrough Therapy Designation for the regimen. It is the only anti-BCMA option approved in second line and beyond multiple myeloma in China, and the only fully outpatient anti-BCMA therapy, allowing 30-minute infusions without hospitalisation.
The DREAMM-7 phase III trial showed the Blenrep combination nearly tripled median progression-free survival to 36.6 months versus 13.4 months for a daratumumab-based triplet, and reduced the risk of death by 42%. Three-year overall survival was 74% for the Blenrep regimen versus 60% for the comparator, with safety broadly consistent with known profiles and manageable eye-related side effects.